Cardio Diagnostics Holdings (CDIO) EPS (Basic) (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted EPS (Basic) of -$0.63 for Q1 2026, up 24.77% sequentially from -$0.84 in Q4 2025, and up 35.09% YoY from -$0.47 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) EPS (Basic) (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported EPS (Basic) for 6 years, with the latest figure at -$0.63 in Q1 2026.
- Quarterly EPS (Basic) rose 35.09% year-over-year to -$0.63 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.34 (up 32.57% YoY) and the FY2025 annual result came in at -$2.93, up 68.66% from the prior year.
- EPS (Basic) improved to -$0.63 in Q1 2026 per CDIO's latest filing, from -$0.84 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.63 in Q1 2026 and troughed at -$23.11 in Q4 2022.
- A 5-year average of -$4.25 and a median of -$1.73 in 2024 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2023: EPS (Basic) slumped 518.55% in 2022, then surged 85.78% in 2023.
- Over 5 years, EPS (Basic) stood at -$23.11 in 2022, then surged by 85.78% to -$3.29 in 2023, then soared by 48.4% to -$1.7 in 2024, then jumped by 50.64% to -$0.84 in 2025, then advanced by 24.77% to -$0.63 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.63, -$0.84, and -$0.98 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.23 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.06 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.18 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -0.72 |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -0.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.51 |
| Mar 31, 2026 | -0.63 |
| Dec 31, 2025 | -0.84 |
| Sep 30, 2025 | -0.98 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | -0.97 |
| Dec 31, 2024 | -1.70 |
| Sep 30, 2024 | -1.73 |
| Jun 30, 2024 | -1.71 |
| Mar 31, 2024 | -5.93 |
| Dec 31, 2023 | -3.29 |
| Sep 30, 2023 | -4.87 |
| Jun 30, 2023 | -11.78 |
| Mar 31, 2023 | -3.25 |
| Dec 31, 2022 | -23.11 |
| Sep 30, 2022 | -5.31 |
| Jun 30, 2022 | -3.89 |
| Mar 31, 2022 | -1.34 |
| Dec 31, 2021 | -3.74 |